The Comparison of Serum Exosome Protein Profile in Diagnosis of NSCLC Patients

A thorough study of the exosomal proteomic cargo may enable the identification of proteins that play an important role in cancer development. The aim of this study was to compare the protein profiles of the serum exosomes derived from non-small lung cancer (NSCLC) patients and healthy volunteers (control) using the high-performance liquid chromatography coupled to mass spectrometry (HPLC-MS) method to identify potentially new diagnostic and/or prognostic protein biomarkers. Proteins exclusively identified in NSCLC and control groups were analyzed using several bioinformatic tools and platforms (FunRich, Vesiclepedia, STRING, and TIMER2.0) to find key protein hubs involved in NSCLC progression and the acquisition of metastatic potential. This analysis revealed 150 NSCLC proteins, which are significantly involved in osmoregulation, cell–cell adhesion, cell motility, and differentiation. Among them, 3 proteins: Interleukin-34 (IL-34), HLA class II histocompatibility antigen, DM alpha chain (HLA-DMA), and HLA class II histocompatibility antigen, DO beta chain (HLA-DOB) were shown to be significantly involved in the cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) infiltration processes. Additionally, detected proteins were analyzed according to the presence of lymph node metastasis, showing that differences in frequency of detection of protein FAM166B, killer cell immunoglobulin-like receptor 2DL1, and olfactory receptor 52R1 correlate with the N feature according to the TNM Classification of Malignant Tumors. These results prove their involvement in NSCLC lymph node spread and metastasis. However, this study requires further investigation.

[1]  E. Safari,et al.  The immunomodulatory role of exosomal microRNA networks in the crosstalk between tumor-associated myeloid-derived suppressor cells and tumor cells. , 2023, International immunopharmacology.

[2]  T. Yang,et al.  Current status of immunotherapy for non-small cell lung cancer , 2022, Frontiers in Pharmacology.

[3]  Yuchen Liu,et al.  Clinical M2 Macrophage-Related Genes Can Serve as a Reliable Predictor of Lung Adenocarcinoma , 2022, Frontiers in Oncology.

[4]  J. Boncela,et al.  Integrated Bioinformatics Analysis of the Hub Genes Involved in Irinotecan Resistance in Colorectal Cancer , 2022, Biomedicines.

[5]  S. Indraccolo,et al.  Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? , 2022, British Journal of Cancer.

[6]  J. Yoon,et al.  R-Spondin2, a Positive Canonical WNT Signaling Regulator, Controls the Expansion and Differentiation of Distal Lung Epithelial Stem/Progenitor Cells in Mice , 2022, International journal of molecular sciences.

[7]  Chunyang Jiang,et al.  Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms , 2021, Molecular Cancer.

[8]  Jiyoun Lee,et al.  The macrophage odorant receptor Olfr78 mediates the lactate-induced M2 phenotype of tumor-associated macrophages , 2021, Proceedings of the National Academy of Sciences.

[9]  E. Brzeziańska-Lasota,et al.  Proteomic biomarkers of non-small cell lung cancer patients. , 2021, Advances in respiratory medicine.

[10]  Álvaro González,et al.  Exosomes in Lung Cancer: Actors and Heralds of Tumor Development , 2021, Cancers.

[11]  Minghui Zhang,et al.  Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer , 2021, Frontiers in Oncology.

[12]  M. Segura,et al.  Dickkopf Proteins and Their Role in Cancer: A Family of Wnt Antagonists with a Dual Role , 2021, Pharmaceuticals.

[13]  Xiaotian Liu,et al.  The role of exosomes in lung cancer metastasis and clinical applications: an updated review , 2021, Journal of Translational Medicine.

[14]  G. Gunaydin.  CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion , 2021, Frontiers in Oncology.

[15]  Shenglin Ma,et al.  Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives. , 2021, Cancer letters.

[16]  N. Rezaei,et al.  A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications , 2021, Translational lung cancer research.

[17]  Ruhong Li,et al.  Cancer-associated fibroblasts: overview, progress, challenges, and directions , 2021, Cancer Gene Therapy.

[18]  Rushikesh S. Joshi,et al.  The Role of Cancer-Associated Fibroblasts in Tumor Progression , 2021, Cancers.

[19]  G. Jiang,et al.  Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer , 2021, Translational lung cancer research.

[20]  Xianrang Song,et al.  Tumor-Derived Exosomal miRNAs as Diagnostic Biomarkers in Non-Small Cell Lung Cancer , 2020, Frontiers in Oncology.

[21]  A. Bergamaschi,et al.  Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance , 2020, npj Precision Oncology.

[22]  Xiaole Shirley Liu,et al.  TIMER2.0 for analysis of tumor-infiltrating immune cells , 2020, Nucleic Acids Res..

[23]  V. Darley-Usmar,et al.  Lung Tumor Cell-Derived Exosomes Promote M2 Macrophage Polarization , 2020, Cells.

[24]  Amber M. Johnson,et al.  Cancer Cell–Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti–PD-1 Therapy in Lung Adenocarcinoma , 2020, The Journal of Immunology.

[25]  N. Dilsiz.  Role of exosomes and exosomal microRNAs in cancer , 2020, Future science OA.

[26]  Zhenhua Zhou,et al.  Proteomic analysis of plasma exosomes to differentiate malignant from benign pulmonary nodules , 2019, Clinical Proteomics.

[27]  Xianrang Song,et al.  Tumor‐derived exosomal proteins as diagnostic biomarkers in non‐small cell lung cancer , 2018, Cancer science.

[28]  T. Whiteside,et al.  Natural Killer Cell Derived Exosomes As a Novel Therapeutic for Acute Myeloid Leukemia , 2018, Blood.

[29]  Douglas B. Johnson,et al.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer , 2018, Clinical Cancer Research.

[30]  Raffaele Palmirotta,et al.  Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology , 2018, Therapeutic advances in medical oncology.

[31]  Benjamin A Hall,et al.  Exploring the role of stromal osmoregulation in cancer and disease using executable modelling , 2018, Nature Communications.

[32]  Salvatore Piscuoglio,et al.  Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations , 2018, Diagnostics.

[33]  I. Adcock,et al.  The Potential Biomarkers and Immunological Effects of Tumor-Derived Exosomes in Lung Cancer , 2018, Front. Immunol..

[34]  Xianrang Song,et al.  Circulating exosomes contain protein biomarkers of metastatic non‐small‐cell lung cancer , 2018, Cancer science.

[35]  Yan Sun,et al.  Comparative Proteomic Analysis of Exosomes and Microvesicles in Human Saliva for Lung Cancer. , 2018, Journal of proteome research.

[36]  Lieping Chen,et al.  DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune cell activation , 2018, Nature Medicine.

[37]  Hao Chen,et al.  Downregulation of BarH‐like homeobox 2 promotes cell proliferation, migration and aerobic glycolysis through Wnt/β‐catenin signaling, and predicts a poor prognosis in non‐small cell lung carcinoma , 2018, Thoracic cancer.

[38]  F. Askin,et al.  Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. , 2017, Seminars in cancer biology.

[39]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[40]  Qinghua Zhou,et al.  Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway , 2017, Oncotarget.

[41]  D. Adams,et al.  Revisiting olfactory receptors as putative drivers of cancer , 2017, Wellcome open research.

[42]  M. Takeya,et al.  CAFs and TAMs: maestros of the tumour microenvironment , 2017, The Journal of pathology.

[43]  S. Kobayashi,et al.  Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: a meta-analysis. , 2017, Translational lung cancer research.

[44]  P. Bunn,et al.  KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer , 2016, Oncotarget.

[45]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[46]  Yu-Sun Chang,et al.  Identification and Characterization of Potential Biomarkers by Quantitative Tissue Proteomics of Primary Lung Adenocarcinoma* , 2016, Molecular & Cellular Proteomics.

[47]  S. Martial.  Involvement of ion channels and transporters in carcinoma angiogenesis and metastasis. , 2016, American journal of physiology. Cell physiology.

[48]  Ching-Seng Ang,et al.  FunRich: An open access standalone functional enrichment and interaction network analysis tool , 2015, Proteomics.

[49]  Larissa V Furtado,et al.  Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility?: A Report of the Association for Molecular Pathology. , 2015, The Journal of molecular diagnostics : JMD.

[50]  S. Mathivanan,et al.  Exosomes in bodily fluids are a highly stable resource of disease biomarkers , 2015, Proteomics. Clinical applications.

[51]  C. Théry,et al.  Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. , 2014, Annual review of cell and developmental biology.

[52]  A. Majid,et al.  Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. , 2014, Lung cancer.

[53]  Mong-Hong Lee,et al.  Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies , 2014, Cancer biology & medicine.

[54]  Zuhong Lu,et al.  miRNA in Plasma Exosome is Stable under Different Storage Conditions , 2014, Molecules.

[55]  G. Pelosi,et al.  Olfactory receptor 51E1 as a novel target for diagnosis in somatostatin receptor-negative lung carcinoids. , 2013, Journal of molecular endocrinology.

[56]  Wai Leong Tam,et al.  The epigenetics of epithelial-mesenchymal plasticity in cancer , 2013, Nature Medicine.

[57]  E. V. van Beek,et al.  The 7th lung cancer TNM classification and staging system: Review of the changes and implications. , 2012, World journal of radiology.

[58]  G. Watanabe,et al.  Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2009, Clinical Cancer Research.

[59]  Peng-Fei Zhang,et al.  Identificating 14-3-3 sigma as a lymph node metastasis-related protein in human lung squamous carcinoma. , 2009, Cancer letters.

[60]  H. Dressman,et al.  Characterizing the developmental pathways TTF-1, NKX2–8, and PAX9 in lung cancer , 2009, Proceedings of the National Academy of Sciences.

[61]  Jude Kendall,et al.  Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer , 2007, Proceedings of the National Academy of Sciences.

[62]  P. Robbins,et al.  MHC Class II+ Exosomes in Plasma Suppress Inflammation in an Antigen-Specific and Fas Ligand/Fas-Dependent Manner1 , 2007, The Journal of Immunology.

[63]  Hoguen Kim,et al.  Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma , 2004, Proteomics.

[64]  Y. Okada,et al.  Apoptosis, cell volume regulation and volume-regulatory chloride channels. , 2001, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[65]  T. Jessell,et al.  Control of Interneuron Fate in the Developing Spinal Cord by the Progenitor Homeodomain Protein Dbx1 , 2001, Neuron.

[66]  O. Mandelboim,et al.  The binding site of NK receptors on HLA-C molecules. , 1997, Immunity.

[67]  E. Delpire,et al.  Water Homeostasis and Cell Volume Maintenance and Regulation. , 2018, Current topics in membranes.

[68]  S. Philippou,et al.  Helional-induced activation of human olfactory receptor 2J3 promotes apoptosis and inhibits proliferation in a non-small-cell lung cancer cell line. , 2017, European journal of cell biology.

[69]  P. Basse,et al.  Antitumor activity of NK cells , 2006, Immunologic research.